THE EUROPEAN MEDICINES AGENCY'S STRATEGIES TO TACKLE THE CHALLENGES OF AD DRUG DEVELOPMENT

被引：0
|
作者：
Mantua, Valentina [1 ]
机构：
[1] AIFA, Rome, Italy
来源：
NEUROBIOLOGY OF AGING | 2016年 / 39卷
关键词：
Alzheimer's disease; Regulatory;
D O I：
10.1016/j.neurobiolaging.2016.01.038
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S6 / S6
页数：1
相关论文
共 50 条
  • [31] Rent rise frustrates EU drug agency European Medicines Agency hits relocation stumbling block
    Vesper, Inga
    NATURE, 2018, 556 (7702) : 418 - 418
  • [32] The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance
    Kostyanev, T.
    Bonten, M. J. M.
    O'Brien, S.
    Steel, H.
    Ross, S.
    Francois, B.
    Tacconelli, E.
    Winterhalter, M.
    Stavenger, R. A.
    Karlen, A.
    Harbarth, S.
    Hackett, J.
    Jafri, H. S.
    Vuong, C.
    MacGowan, A.
    Witschi, A.
    Angyalosi, G.
    Elborn, J. S.
    dewinter, R.
    Goossens, H.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (02) : 290 - 295
  • [33] From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit
    Lythgoe, Mark P.
    Krell, Jonathan
    Bower, Mark
    Murphy, Ravindhi
    Marriott, John
    Blagden, Sarah P.
    Aggarwal, Ajay
    Sullivan, Richard
    LANCET ONCOLOGY, 2023, 24 (04): : E150 - E160
  • [34] Where Statisticians can Contribute to Address Future Challenges for Drug Regulatory Agencies: A View from the European Medicines Agency (EMEA)
    Eichler, Hans-Georg
    Hemmings, Robert J.
    Vamvakas, Spiros
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2010, 2 (03): : 355 - 358
  • [35] Outpatient fluoroquinolone use in relation to European Medicines Agency's recommendation: An Estonian nationwide drug utilization study
    Kurvits, Katrin
    Uuskula, Maia
    Vestman, Helve
    Laius, Ott
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 (06) : 643 - 650
  • [36] Review: UK medicines likely to be affected by the proposed European Medicines Agency’s guidelines on phthalates
    Lisa Jamieson
    William McCully
    BMC Pharmacology and Toxicology, 16
  • [37] Review: UK medicines likely to be affected by the proposed European Medicines Agency's guidelines on phthalates
    Jamieson, Lisa
    McCully, William
    BMC PHARMACOLOGY & TOXICOLOGY, 2015, 16
  • [38] Current neurotransmitter strategies in AD drug development
    Francis, PT
    Alder, JT
    Cole, KL
    Heslop, KE
    Minger, SL
    Ramirez, MJ
    PROGRESS IN ALZHEIMER'S AND PARKINSON'S DISEASES, 1998, 49 : 851 - 859
  • [39] Overview of the European Medicines Agency's Experience With Biowaivers in Centralized Applications
    Lenic, Ines
    Blake, Kevin
    Garcia-Arieta, Alfredo
    Potthast, Henrike
    Welink, Jan
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2019, 12 (05): : 490 - 496
  • [40] AGENCY AUTONOMY ACTUALLY: MANAGERIAL STRATEGIES, LEGITIMACY, AND THE EARLY DEVELOPMENT OF THE EUROPEAN UNION'S AGENCIES FOR DRUG AND FOOD SAFETY REGULATION
    Groenleer, Martijn L. P.
    INTERNATIONAL PUBLIC MANAGEMENT JOURNAL, 2014, 17 (02) : 255 - 292
12345